Results

1–5 of 5 results for wAMD

Subgroup Analyses of the Phase 1 DAVIO Trial of EYP-1901 Showing Reduced Treatment Burden in Wet Age-related Macular Degeneration
Philip P Storey, MD, MPH
Annual Meeting Talks
2023
First Time Results of VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy
Omer Trivizki, MD, MBA
Updates from the Field
2025
Suprachoroidal CLS-AX (axitinib injectable suspension), as a Potential Long-Acting Therapy for Neovascular Age-Related Macular Degeneration (nAMD)
David M. Brown, MD
Annual Meeting Talks
2020
One Year and Beyond: Results of Phase 1b Study of KSI-301, an AntiVEGF Antibody Biopolymer Conjugate With Extended Durability, in wAMD, DME, and RVO
Mark R. Barakat, MD
Updates from the Field
2020
Episode 23: CANTREAT Study. Ranibizumab Monthly vs Treat-and-Extend for wAMD with Dr. Peter Kertes
Keyvan Koushan, MD, FRCSC
Member Podcasts
2019